FDA Takes Dim View Of Ampligen For Chronic Fatigue Syndrome

In review documents released ahead of a Dec. 20 advisory committee meeting, agency questions the validity of Hemispherx’s post-hoc efficacy analyses and raises concerns about adverse events and the reliability of the safety data.